GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

And it trades at a P/S of 2.1 against a peer average of 6.3. I used a discounted cash flow analysis to translate these ratios into hard cash terms for a fair value for GSK shares. This shows the stock ...

GSK Vaccine Updates ... discussions. SMMT Stock Surges on NSCLC Data: Summit Therapeutics’ shares skyrocketed on Sept. 9 after it reported data from the primary analysis of the phase III ...

GSK PLC GSK shares slipped 1.84% to £15.75 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.91% to 8,328.72. Supported ...